Stuttgart - Delayed Quote EUR

IDEAYA Biosciences, Inc. (30J.SG)

Compare
23.20
+0.80
+(3.57%)
At close: January 31 at 9:34:14 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 30J.SG

Recent News: 30J.SG

View More
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire 16 hours ago
Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025
Insider Monkey yesterday
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
PR Newswire 4 days ago
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Simply Wall St. 5 days ago
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
PR Newswire 19 days ago

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
PREMIUM
MT Newswires last month
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
PR Newswire last month
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
PR Newswire last month
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
PR Newswire last month
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years
Simply Wall St. last month
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
PR Newswire last month
View More

Related Tickers

SER Serina Therapeutics, Inc.
4.7000
+2.17%
 
AADI Aadi Bioscience, Inc.
2.8800
0.00%
 
CELC Celcuity Inc.
11.95
+1.96%
 
THTX Theratechnologies Inc.
1.4400
+0.70%
 
APGE Apogee Therapeutics, Inc.
41.36
-2.68%
 
VRDN Viridian Therapeutics, Inc.
19.38
-3.49%
 
ADCT ADC Therapeutics SA
1.6800
-2.33%
 
CRNX Crinetics Pharmaceuticals, Inc.
40.30
+0.10%
 
OVID Ovid Therapeutics Inc.
0.6634
-5.24%
 
COGT Cogent Biosciences, Inc.
9.31
-3.22%